10x Genomics: Technology Leader in Next-Generation Genomics

The high-margin "razor-and-blades business model" provides the technology leader with reliable, recurring revenues through the steady sale of reagents and consumables. Despite short-term hurdles due to reduced research budgets, the company is well-positioned for profitability thanks to a liquid reserve of over $500 million and drastically reduced losses. As a pioneer in future fields such as spatial biology, AI-driven drug development, and clinical diagnostics, the stock offers substantial growth potential for long-term oriented investors....